News & Updates

Relying on targeted screening models for syphilis in emergency departments (EDs) leaves a substantial number of active cases undetected, new research shows.

When treating late latent syphilis during pregnancy, extending the interval between benzathine penicillin G (BPG) doses to 9 days may put newborns at risk of congenital infection relative to 6–8-day intervals, according to new research.

Treatment with ensitrelvir among household contacts (HHC) of index patients (IP) with COVID-19 within 72 h after the onset of IP symptoms demonstrates efficacy and an acceptable safety profile as postexposure prophylaxis (PEP) in SCORPIO-PEP, a phase III placebo-controlled trial.

A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.

Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.